TY - JOUR T1 - Cryptic transmission of SARS-CoV-2 in Washington State JF - medRxiv DO - 10.1101/2020.04.02.20051417 SP - 2020.04.02.20051417 AU - Trevor Bedford AU - Alexander L. Greninger AU - Pavitra Roychoudhury AU - Lea M. Starita AU - Michael Famulare AU - Meei-Li Huang AU - Arun Nalla AU - Gregory Pepper AU - Adam Reinhardt AU - Hong Xie AU - Lasata Shrestha AU - Truong N Nguyen AU - Amanda Adler AU - Elisabeth Brandstetter AU - Shari Cho AU - Danielle Giroux AU - Peter D. Han AU - Kairsten Fay AU - Chris D. Frazar AU - Misja Ilcisin AU - Kirsten Lacombe AU - Jover Lee AU - Anahita Kiavand AU - Matthew Richardson AU - Thomas R. Sibley AU - Melissa Truong AU - Caitlin R. Wolf AU - Deborah A. Nickerson AU - Mark J. Rieder AU - Janet A. Englund AU - the Seattle Flu Study Investigators AU - James Hadfield AU - Emma B. Hodcroft AU - John Huddleston AU - Louise H. Moncla AU - Nicola F. Müller AU - Richard A. Neher AU - Xianding Deng AU - Wei Gu AU - Scot Federman AU - Charles Chiu AU - Jeff Duchin AU - Romesh Gautom AU - Geoff Melly AU - Brian Hiatt AU - Philip Dykema AU - Scott Lindquist AU - Krista Queen AU - Ying Tao AU - Anna Uehara AU - Suxiang Tong AU - Duncan MacCannell AU - Gregory L. Armstrong AU - Geoffrey S. Baird AU - Helen Y. Chu AU - Jay Shendure AU - Keith R. Jerome Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/16/2020.04.02.20051417.abstract N2 - Following its emergence in Wuhan, China, in late November or early December 2019, the SARS-CoV-2 virus has rapidly spread throughout the world. Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections. Here, we analyze 346 SARS-CoV-2 genomes from samples collected between 20 February and 15 March 2020 from infected patients in Washington State, USA. We found that the large majority of SARS-CoV-2 infections sampled during this time frame appeared to have derived from a single introduction event into the state in late January or early February 2020 and subsequent local spread, indicating cryptic spread of COVID-19 before active community surveillance was implemented. We estimate a common ancestor of this outbreak clade as occurring between 18 January and 9 February 2020. From genomic data, we estimate an exponential doubling between 2.4 and 5.1 days. These results highlight the need for large-scale community surveillance for SARS-CoV-2 and the power of pathogen genomics to inform epidemiological understanding.Competing Interest StatementJanet A. Englund is a consultant for Sanofi Pasteur and Meissa Vaccines, Inc., and receives research support from GlaxoSmithKline, AstraZeneca, and Novavax. Helen Chu is a consultant for Merck and GlaxoSmithKline. Jay Shendure is a consultant with Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Nanostring, Phase Genomics, Adaptive Biotechnologies, and Stratos Genomics, and has a research collaboration with Illumina. Michael Famulare, Lea Starita, Pavitra Roychoudhury, Amanda Adler, Peter Han, Kirsten Lacombe, Elisabeth Brandstetter, Caitlin R. Wolf, Richard A Neher, James Hadfield, Nicola F. Müller, Jover Lee, Thomas Sibley, Kairsten Fay, Deborah A. Nickerson, Mark J. Rieder, and Trevor Bedford declare no competing interests.Funding StatementThe Seattle Flu Study is run through the Brotman Baty Institute for Precision Medicine and funded by Gates Ventures, the private office of Bill Gates. The funder was not involved in the design of the study and does not have any ownership over the management and conduct of the study, the data, or the rights to publish. JS is an Investigator of the Howard Hughes Medical Institute. TB is a Pew Biomedical Scholar and is supported by NIH R35 GM119774-01. EBH and RAN are supported by University of Basel core funding. Sequencing analyses of SARS-CoV-2 genomes from California was supported by an NIH grant R33-AI129455 and the Charles and Helen Schwab Foundation to CYC, and an NIH grant K08-CA230156 and the Burroughs-Wellcome CAMS Award to WG. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesConsensus SARS-CoV-2 genome sequences were deposited into GISAID immediately on generation. They have been submitted to Genbank as well (accession pending). All data used in the paper is also available here: https://github.com/blab/ncov-cryptic-transmission. ER -